Results 61 to 70 of about 5,534,172 (226)

A Novel Nanoantibiotic Formulation With Magnetic and Targeting Potential: Ampicillin‐Conjugated L‐glu–Fe3O4 NPs

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
A novel nanoformulation consisting of ampicillin (Amp), l‐glutamic acid (l‐glu), and iron oxide nanoparticles was prepared. l‐glu–Fe3O4–Amp NPs exhibited a controlled drug release profile over a certain period of time. The antibacterial effectiveness of the formulation was proven by agar well diffusion and the LIVE/DEAD BacLight fluorescent assays. The
Mehmet Demirel, Ozlem Baris, Mesut Taskin, Seyda Albayrak, Ferhunde Aysin, Azada Aliyeva, Buket Bakan   +6 more
wiley   +1 more source

Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current Recommendations on Diagnosis, Treatment, and Patient Management

International Journal of General Medicine, 2022
Kriti Pathak,1,* Stephanie Hart,1,* Leah Lande1,2 1Division of Pulmonary and Critical Care Medicine, Lankenau Medical Center, Wynnewood, PA, USA; 2Lankenau Institute for Medical Research, Wynnewood, PA, USA*These authors contributed equally ...
Pathak K, Hart S, Lande L
doaj  

Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management

MedComm, Volume 7, Issue 10, October 2026.
A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley   +1 more source

Flow chart of the study of patients with mild Mycobacterium avium complex pulmonary disease.

, 2019
MAC = Mycobacterium avium complex.
Takahiro Asami (325491), Shinji Maeda (445222), Yoshifumi Kimizuka (6635747), Naoki Hasegawa (1698301), Atsuyuki Kurashima (3551789), Tomoko Betsuyaku (87406), Satoshi Iwata (425199), Noboru Nakata (673422), Kozo Morimoto (3551798), Kazuma Yagi (3551795), Takayuki Abe (170440), Hiroshi Fujiwara (236227), Shunsuke Uno (6635750), Naohiko Inase (795423), Tomoyasu Nishimura (3551777), Ho Namkoong (3551780), Yoshihiko Hoshino (259654), Toshihide Fujie (6635753), Yohei Funatsu (4346005), Yumi Sakakibara (4822074), Makoto Ishii (229384)   +20 more
core   +1 more source

Mycobacterium avium complex, an emerging pathogen in Massachusetts [PDF]

Journal of Clinical Microbiology, 1985
We report a study of 1,953 patients whose laboratory records from 1972 through 1983 at the Massachusetts Mycobacteria Reference Laboratory indicated the isolation of Mycobacterium avium complex (MAC) organisms. At least one clinical specimen from each patient during this period exhibited the organism.
G C, du Moulin, I H, Sherman, D C, Hoaglin, K D, Stottmeier   +3 more
openaire   +2 more sources

Alveolar Macrophages: Development, Respiratory Homeostasis, Signal Pathways, Diseases, and Therapeutic Opportunities

MedComm, Volume 7, Issue 10, October 2026.
Alveolar macrophages: development, respiratory homeostasis, signal pathways, diseases, and therapeutic opportunities: During embryonic development, fetal progenitors migrate to the developing lungs via a CX3CR1‐dependent mechanism to establish the TrAM pool.
Sihan Yang, Ruomeng Li, Chuanjiang Yu, Jing Li, Xikun Zhou   +4 more
wiley   +1 more source

Characteristics of patients with mildly symptomatic Mycobacterium avium complex pulmonary disease^*.

, 2019
Characteristics of patients with mildly symptomatic Mycobacterium avium complex pulmonary disease*.
Takahiro Asami (325491), Shinji Maeda (445222), Yoshifumi Kimizuka (6635747), Naoki Hasegawa (1698301), Atsuyuki Kurashima (3551789), Tomoko Betsuyaku (87406), Satoshi Iwata (425199), Noboru Nakata (673422), Kozo Morimoto (3551798), Kazuma Yagi (3551795), Takayuki Abe (170440), Hiroshi Fujiwara (236227), Shunsuke Uno (6635750), Naohiko Inase (795423), Tomoyasu Nishimura (3551777), Ho Namkoong (3551780), Yoshihiko Hoshino (259654), Toshihide Fujie (6635753), Yohei Funatsu (4346005), Yumi Sakakibara (4822074), Makoto Ishii (229384)   +20 more
core   +1 more source

Minimum inhibitory concentration (MIC) values of 13 drugs determined for 38 Mycobacterium avium complex clinical isolates.

, 2023
Minimum inhibitory concentration (MIC) values of 13 drugs determined for 38 Mycobacterium avium complex clinical isolates.
Auttawit Sirichoat (9033704), Yothin Hinwan (17442200), Orawee Kaewprasert (9931459), Kiatichai Faksri (775893)   +3 more
core   +1 more source

Mycobacterium chimaera: a case report from Italy

Monaldi Archives for Chest Disease
Mycobacterium chimaera is an environmental non-tuberculous mycobacterium belonging to Mycobacterium avium complex (MAC). It has been widely known to be associated with disseminated infection after cardiac surgery, related to heater-cooler units used ...
Martina Maria Seminara, Dina Visca, Alice Claudia Repossi, Antonio Spanevello   +3 more
doaj   +1 more source

In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates

Journal of Microbiology, Immunology and Infection, 2018
Background/Purpose: Treatment success rates for Mycobacterium avium complex (MAC) diseases range from 50% to 55% only. To explore effective antimicrobials against either Mycobacterium intracellulare or M.
Chen-Cheng Huang, Ming-Feng Wu, Hui-Chen Chen, Wei-Chang Huang   +3 more
doaj   +1 more source